Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists

1. A compound of formula (I)

or an optically pure enantiomer, a mixture of enantiomers, an optically pure diastereoisomer, a mixture of diastereolsomers, a diastereoisomeric racemate, a mixture of diastereoisomeric racemates, a meso form; or a pharmaceutically acceptable salt thereof;

wherein:

R 1 , R 2 , R 3 , R 4 independently represent cyano, nitro, halogen, hydrogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclylalkyloxy, R 11 CO—, NR 12 R 13 CO—, R 12 R 13 N—, R 11 OOC—, R 11 SO 2 NH—, or R 14 —CO—NH—, or R 2 and R 3 together as well as R 1 and R 2 together and R 3 and R 4 together may form with the phenyl ring a five, six or seven-membered saturated ring comprising one or two oxygen atoms;

R 5 represents aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 6 represents hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 7 , R 8 independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 9 , R 10 independently represent hydrogen, aryl, arylcycloalkyl, aralkyl, lower alkyl, lower alkenyl, lower alkinyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl, in which one, several, or all hydrogen atoms may be replaced by halogen or in which one or two hydrogen atoms may be replaced by hydroxy, nitro, cyano, trifluoromethyl, trifluoromethoxy, —O-lower alkyl, —NH-lower alkyl, —N(lower alkyl) 2 , —S-lower alkyl, —COO-lower alkyl,

—CONH-lower alkyl, —CON(lower alkyl) 2 , —CO-lower alkyl, —NHCO-lower alkyl, —O-lower alkenyl with 3 to 5 carbon atoms, —NH-lower alkenyl with 3 to 5 carbon atoms, —N(lower alkenyl with 3 to 5 carbon atoms) 2 , —S-lower alkenyl with 3 to 5 carbon atoms, —COO-lower alkenyl with 3 to 5 carbon atoms, —CONH-lower alkenyl with 3 to 5 carbon atoms, —CON(lower alkenyl with 3 to 5 carbon atoms) 2 , —CO-lower alkenyl with 3 to 5 carbon atoms, —NHCO-lower alkenyl with 3 to 5 carbon atoms, —O-lower alkinyl with 3 to 5 carbon atoms, —NH-lower alkinyl with 3 to 5 carbon atoms, —N(lower alkinyl with 3 to 5 carbon atoms) 2 , —S-lower alkinyl with 3 to 5 carbon atoms, —COO-lower alkinyl with 3 to 5 carbon atoms, —CONH-lower alkinyl with 3 to 5 carbon atoms, —CON(lower alkinyl with 3 to 5 carbon atoms) 2 , or —NHCO-lower alkinyl with 3 to 5 carbon atoms;

R 11 represents lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 12 and R 13 independently represent hydrogen, lower alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 14 represents lower alkyl, aryl, cycloalkyl, heterocyclyl, R 12 R 13 N—, R 11 O—; and

—X—Y— is —CH 2 —CH 2 —.

2. A compounds of the formula (II)

or an optically pure enantiomer, a mixture of enantiomers, an optically pure diastereoisomer, a mixture of diastereoisomers, a diastereoisomeric racemate, a mixture of diastereoisomeric racemates, a meso form; or a pharmaceutically acceptable salt thereof;

wherein:

R 1 , R 2 , R 3 , R 4 independently represent cyano, nitro, halogen, hydrogen, hydroxy, lower alkyl, lower alkenyl, lower alkoxy, lower alkenyloxy, trifluoromethyl, trifluoromethoxy, cycloalkyloxy, aryloxy, aralkyloxy, heterocyclyloxy, heterocyclylalkyloxy, R 11 CO—, NR 12 R 13 CO—, R 12 R 13 N—, R 11 OOC—, R 11 SO 2 NH—, or R 14 —CO—NH—, or R 2 and R 3 together as well as R 1 and R 2 together and R 3 and R 4 together may form with the phenyl ring a five, six or seven-membered saturated ring comprising one or two oxygen atoms;

R 5 independently represents aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 6 independently represents hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, trifluoromethyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 7 , R 8 , R 9 , R 10 independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 11 represents lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 12 and R 13 independently represent hydrogen, lower alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl;

R 14 represents lower alkyl, aryl, cycloalkyl, heterocyclyl, R 12 R 13 N—, R 11 O—; and

—X—Y— is —CH 2 —CH 2 —.

3. A compounds of the formula (III)

or an optically pure enantiomer, a mixture of enantiomers, an optically pure diastereoisomer, a mixtures of diastereoisomers, a diastereoisomeric racemate, a mixture of diastereoisomeric racemates, a meso form; or a pharmaceutically acceptable salt thereof;

wherein:

R′ 1 and R′ 2 independently represent hydrogen, hydroxy, lower alkoxy, lower alkenyloxy or halogen or may form with the phenyl ring a five, six or seven membered-ring comprising one or two oxygen atoms;

R′ 3 represents aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl;

R′ 4 , R′ 5 independently represent hydrogen, aryl, aralkyl, lower alkyl, lower alkenyl, cycloalkyl, heterocyclyl or heterocyclyl-lower alkyl; and

—X—Y— is —CH 2 —CH 2 .

4. The compound according to claim 1 , selected from the group consisting of:

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-naphthalen-1-ylmethyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-2-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-2-yl-2-phenyl-acetamide;

N-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo [c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-2-phenyl-acetamide;

N-Cyclopentyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-furan-2-ylmethyl-2-phenyl-acetamide;

{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-acetic acid ethyl ester;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-N-pyridin-4-ylmethyl-acetamide

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-N-pyridin-3-ylmethyl-acetamide;

N-Cyclopropyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(4-methoxy-indan-1-yl)-acetamide;

2-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-3-hydroxy-propionic acid methyl ester;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-ethylcarbamoylmethyl-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-[(ethyl-methyl-carbamoyl)-methyl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-8-hydroxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-acetamide;

2-[8-Benzyloxy-1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-acetamide;

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-propionic acid methyl ester;

N-(1H-Benzoimidazol-2-ylmethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-N,N-dimethyl-propionamide;

3-{2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetylamino}-N-ethyl-N-methyl-propionamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-isoxazol-5-ylmethyl-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(1H-indol-3-ylmethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-isoquinolin-1-ylmethyl-2-phenyl-acetamide;

N-Cyanomethyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

N-(2-Acetylamino-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-N-(2,2,2-trifluoro-ethyl)-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(2-methylsulfanyl-ethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-N-quinolin-2-ylmethyl-acetamide;

N-(2-Cyano-ethyl)-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(3-methoxy-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(3-ethoxy-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-N-pyrazin-2-ylmethyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-N-prop-2-ynyl-acetamide;

N-tert-Butyl-2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(3-methyl-butyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(3,3-dimethyl-butyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(1-ethyl-propyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(2-ethylsulfanyl-ethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(2-hydroxy-ethyl)-2-phenyl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7,8-dinlethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-(3-hydroxy-propyl)-2-phenyl-acetamide;

2-[8-Allyloxy-[l]1-(3,4-dimethoxy-benzyl)-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-7-methoxy-8-propoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-acetamide;

2-[1-(3,4-Dimethoxy-benzyl)-8-isopropoxy-7-methoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-acetamide;

2-[1-(S)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-1-yl-acetamide; and

2-[1-(S)-(3,4-Dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzo[c]azepin-2-yl]-N-indan-2-yl-acetamide.

5. The compound of claim 4 wherein said compound is 2-[1-(3,4-dimethoxy-benzyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-benzocazepin-2-yl]-2-phenyl-N-prop-2-ynyl-acetamide.